Connect with us

EU Politics

The EU’s Response to COVID-19

Published

on

The European Commission is working on all fronts to support efforts to tackle the COVID-19 outbreak. This includes ongoing coordination with Member States to share information, assess needs and ensure a coherent EU-wide response. The Commission is also funding research, offering support through the EU Civil Protection Mechanism and supporting China with emergency medical supplies to tackle the outbreak at its source.

What has the Commission been doing since the outbreak of COVID-19 was reported in China?

1) At EU level, under the Cross-border Health Threat Decision, the Commission coordinates with Member States through three key mechanisms:

  1.     The Early Warning and Response System
  2.     The Health Security Committee
  3.     The Health Security Committee’s Communicators’ network.

These tools support cooperation, rapid exchange of information, swift monitoring and coordination of preparedness and response measures to COVID-19.

2) The Commission, with support from relevant EU agencies, in particular the European Centre for Disease Prevention and Control (ECDC), the European Medicines Agency (EMA) and the European Union Aviation Safety Agency (EASA), is providing technical guidance related to: risk assessments; case definition for diagnosis and aligned reporting of suspected and confirmed cases; infection prevention and control in health care settings; advice for travellers; updated information on therapeutics and vaccines; contact tracing on aircrafts; management of points of entry and aviation sector recommendations.

Moreover, Member States’ Joint Action Healthy Gateways, funded by the EU, is providing guidance and training on points of entry measures, as well as another Joint Action, SHARP (strengthened international health regulations and preparedness in the EU) on laboratory preparedness.

3) The Commission has been coordinating the delivery of assistance to China as well as financing the transport costs of EU Member States’ repatriation flights.

4) To boost global preparedness, prevention and containment of the virus, new funding worth €232 million will be allocated to different sectors, namely:

– €114 million will support the World Health Organization (WHO), in particular the global preparedness and response global plan. This intends to boost public health emergency preparedness and response work in countries with weak health systems and limited resilience. Part of this funding is subject to the agreement of the EU budgetary authorities. 

– €15 million are planned to be allocated in Africa, including to the Institute Pasteur Dakar, Senegal to support measures such as rapid diagnosis and epidemiological surveillance.

– €100 million, out of which up to €90 million Public Private Partnership with the pharmaceutical industry and 10 million for research on epidemiology, diagnostics, therapeutics and clinical management in containment and prevention. *

– €3 million allocated to the EU Civil Protection Mechanism for repatriation flights of EU citizens from Wuhan, China.

Is the EU prepared and equipped to contain the spread of COVID-19?

Member States continuously inform the Commission and share information regarding their levels of preparedness.

According to the information provided by the national authorities, there is a strong overall level of preparedness with countries having response measures in place to provide treatment for the cases in the EU and to mitigate any further transmission within and into the EU.  

On 13 February, an extraordinary EPSCO Health Council brought together all Member States at a political level to discuss and coordinate measures to limit the spread of the COVID-19 outbreak and further preparedness measures to be considered for the future.

In response to the Council Conclusions of this meeting, the key actions on which the Commission is in the process of following up include continued risk assessment and guidance on travel advice; increased preparedness should the outbreak escalate to the next phase; and activation of existing funding mechanisms to support Member States on preparedness and response to the COVID-19. Other key actions include examining joint procurement for potential needs of protective equipment and strengthened support to the Health Security Committee in providing aligned information across the EU on the virus, detection, use of equipment, etc.

How is the Commission supporting the repatriation of EU nationals from China?

The European Commission has a 24/7 Emergency Response Coordination Centre that is coordinating repatriation flights with EU Member States.

The Commission provides funding to EU Member States to cover up to 75% of the transport costs of these repatriation flights via the EU Civil Protection Mechanism.

The EU Civil Protection Mechanism has facilitated the repatriation of 447 EU citizens from Wuhan, China. In late January, two French aircraft brought back 346 EU citizens, while Germany also conducted one repatriation flight, which brought back 101 EU citizens.

A third repatriation flight was organised by France, repatriating more than 70 EU citizens who were still in Wuhan.

The EU Civil Protection Mechanism also co-financed the last leg from London to the respective Member States of 95 EU citizens brought back on a UK repatriation flight.

Also under the EU Civil Protection Mechanism, Italy sent two planes for the repatriation of EU citizens quarantined on the Diamond Princess cruise that had been docked in Yokohama, Japan, since early February.

What is the EU doing to support China?

The European Commission coordinates the delivery of emergency medical supplies to China through the EU Civil Protection Mechanism.

As of 21 February, over 30.5 tonnes of personal protective equipment to China has been provided by France, Germany, Italy, Latvia and Estonia. The transport costs were co-financed by the EU Civil Protection Mechanism.

  • The first 12 tonnes came as an immediate first offer of assistance, via the first repatriation flights from France and Germany in late January.
  • On 14 February, Italy sent 1.5 tonnes of protective overalls and masks to the Chinese Red Cross in Beijing.
  • On 19 February, France sent a plane to Wuhan with a 20-tonne cargo of surgical masks, gloves, thermometers and disinfectant, which also included material from Latvia and Estonia.
  • On 23 February, an Austrian aircraft departed from Vienna with protective equipment which included masks, gloves, protective clothing and disinfectant.

The Commission stands ready to provide any further assistance to China.

The European Emergency Response Coordination Centre continues to reach out to Member States to map potential contributions of personal protective equipment that will be delivered to China in the near future.

How is the public health risk in Europe evaluated as regards COVID-19?

The European Centre for Disease Prevention and Control (ECDC) is monitoring the outbreak through epidemic intelligence activities, and provides risk assessments to guide EU Member States and the European Commission in their response activities. The ECDC is in continuous contact with the European Commission, the public health authorities in the EU Member States, China and other countries and the World Health Organization for the assessment of this outbreak. ECDC also publishes daily summaries and risk assessments for EU citizens.

What EU-funded research is ongoing on COVID-19?

On 31 January, the Commission launched a request for expressions of interest for research proposals on the novel coronavirus. A budget of €10 million is made available for research that will improve clinical care of patients infected with the virus, as well as the overall public health response. The Innovative Medicines Initiative (IMI) announced its plan for a fast-track call for proposals on the novel coronavirus to be launched in early March. 

In addition, the EU already funds several ongoing research projects that have reoriented their focus to address the COVID-19 outbreak. For example, the PREPARE project ensures research preparedness of clinical treatment sites and the use of harmonised research protocols across Europe through their network of 3,000 hospitals and 900 laboratories in 42 countries. Another EU-funded project, the European Virus Archive GLOBAL (EVAg) has already made available more than 1,000 kits that support the diagnosis of the novel coronavirus, to 79 countries worldwide.

The Commission coordinates with the World Health Organization and other research funders to ensure that research gaps are covered. This happens mainly through the “Global research collaboration for infectious disease preparedness” (GloPID-R) network, the secretariat of which is EU funded. A global research and innovation forum was organised by the World Health Organization and GloPID-R on 11-12 February, to identify research priorities across 10 different thematic areas.

Are food products imported from China safe?

There has been no report of transmission of COVID-19 via food. Therefore, there is no evidence that food items imported into the European Union in accordance with the applicable animal and public health regulations governing imports from China pose a risk for the health of EU citizens in relation to COVID-19.

Moreover, due to the animal health situation in China, only a few products of animal origin are authorised for import into the EU from China, on the condition that they meet strict health requirements and have been subjected to controls.

Is there a vaccine available?

The Commission, with relevant EU agencies, is actively engaged in the arena of therapeutics and vaccine developments. At this stage, the Commission is focusing its funding efforts on research with a timely impact on the current public health emergency due to COVID-19, including on the development of diagnostics and therapeutics. This is in line with the Commission’s emergency research funding of €10 million that was made available at the early stages of the outbreak. Vaccine development is addressed through CEPI (the Coalition for Epidemic Preparedness Innovation), an initiative the Commission contributes to.

Background

What is COVID-19?

COVID-19, previously named 2019-nCoV, was identified in China at the end of 2019 and is a new strain of coronavirus that has not been previously known in humans.

Where do Coronaviruses come from?

Coronaviruses are viruses that circulate among animals but some of them are also known to affect humans. After they have infected humans, transmission can continue between humans.

A wide range of animals is known to be the source of coronaviruses. For instance, the Middle East respiratory syndrome coronavirus (MERS-CoV) originated from camels and the Severe Acute Respiratory Syndrome (SARS) originated from civet cats.

What is the mode of transmission? How (easily) does it spread?

While animals are the source of the virus, COVID-19 is now spreading from one person to another (human-to-human transmission). There is currently not enough epidemiological information to determine how easily and sustainably this virus is spreading between people. It seems to be transmitted mainly via respiratory droplets that people sneeze, cough or exhale. The incubation period for COVID-19 (i.e. the time between exposure to the virus and the onset of symptoms) is currently estimated at five to six days, ranging up to 14 days.

While it is known that the virus can be transmitted when an infected individual has symptoms, there are still uncertainties regarding whether mild or asymptomatic cases can transmit the virus. If people with COVID-19 are tested and diagnosed in a timely manner and rigorous infection control measures are applied, the likelihood of sustained human-to-human transmission in community settings in the EU/EEA is low. Systematic implementation of infection prevention and control measures were effective in controlling SARS-CoV and MERS-CoV.

What are the symptoms of COVID-19?

From what we know so far, the virus can cause mild, flu-like symptoms such as

  • fever
  • cough
  • difficulty breathing
  • pain in the muscles and
  • tiredness.

More serious cases develop severe pneumonia, acute respiratory distress syndrome, sepsis and septic shock that can lead to the death of the patient. People with existing chronic conditions seem to be more vulnerable to severe illness.

Is there a treatment for the disease caused by COVID-19?

There is no specific treatment for this disease so the approach used to treat patients with coronavirus-related infections is to treat the clinical symptoms (e.g. fever). Supportive care (e.g. supportive therapy and monitoring, oxygen therapy, fluid management and antivirals) can be highly effective for those infected.

Is there a vaccine against COVID-19?

There are currently no vaccines against coronaviruses, including COVID-19. That is why it is very important to prevent infection or contain the further spread after an infection.

EU Politics

Dual-use goods: what are they and why are new rules needed?

Published

on

The EU is working on new export rules for so-called dual-use goods to prevent them being misused in human rights violations.

What are dual-use goods?

Dual-use products are goods designed for civilian use that in the wrong hands could be used to supress human rights or launch terrorist attacks. They can be anything from drones to chemicals.

Although these goods can improve people’s lives, they can be misused. Authoritarian regimes might use them to keep the population under control, while terrorist groups could use them to stage attacks.

Why are new rules needed?

To prevent dual-use goods being repurposed in ways that violate human rights , the EU wants to make sure strict export rules prevent them being sold to people or organisations wanting to misuse them.

The EU is currently working on an update of the existing rules to take into account recent technological developments, including new cyber surveillance tools, and beef up protection of human rights.

Continue Reading

EU Politics

Explainer: EU4Health Programme 2021-2027

Published

on

What is EU4Health?

EU4Health is the fourth EU health programme, which will run from 2021-2027. It is the EU’s ambitious health response to the COVID-19 pandemic and the EUs overall health challenges. EU4Health will make €5.1 billion available over the next seven years to improve and foster health in the Union to reduce the burden of communicable and non-communicable diseases by:

  • protecting people from serious cross-border health threats;
  • improving the availability, accessibility and affordability of medicines, medical devices and other crisis relevant products in the EU;
  • strengthening national health systems.

The EU4Health programme will go beyond the COVID-19 crisis, supporting amongst others actions on disease prevention, notably on cancer, the digital transformation of health systems, the reinforcement of the health system and the healthcare workforce. It will pave the way to a strong European Health Union that will improve and safeguard the health of all EU citizens.

What makes EU4Health different from previous health programmes?

Never before has Europe invested more in health. According to a recent EU survey, 66% of EU citizens would like to see the EU given more say over health-related matters. The pandemic has shown that the EU needs greater coordination during health crises and health-systems that are more resilient.

EU4Health is a stand-alone programme with a budget more than ten times that of previous health programmes. Actions like tackling cross-border health threats, making medicines available and affordable, and strengthening and digitalising health systems will be financially supported.

What are the main objectives of the EU4Health Programme?

The EU4Health programme has the following objectives:

  1. Improve and foster health in the Union by:
  • Supporting actions for disease prevention, health promotion and addressing health determinants;
  • Supporting global commitments and health initiatives.
  1. Protect people in the Union from serious cross-border threats to health by:
  • Strengthening the capability of the Union for prevention, preparedness and response to cross-border health threats, including through a new bio-preparedness authority, the European Health Emergency Preparedness and Response Authority (HERA);
  • Supporting actions complementing national stockpiling on essential crisis relevant products;
  • Establishing a structure and training resources for a reserve of medical, healthcare and support staff.
  1. Enhance the availability, accessibility and affordability of medicinal products, medical devices and crisis-relevant products by:
  • Encouraging sustainable production and supply chains and innovation in the Union, while supporting efficient use of medicinal products.
  1. Strengthening health systems resilience and resource efficiency though:
  • Strengthening health data, the uptake of digital tools and services and the digital transformation of healthcare systems, including by supporting the creation of a European Health Data Space;
  • Promoting the implementation of best practices and promoting data sharing;
  • Enhancing access to quality, patient-centred, outcome-based healthcare and related care services;
  • Supporting integrated work among Member States, and in particular their health systems.

How will non-communicable diseases, such as cancer, be addressed in the new programme?

Non-communicable and life style related diseases are among the biggest challenges facing EU health systems. Non-communicable diseases such as cardiovascular diseases, cancer, chronic respiratory diseases, and diabetes, represent major causes of disability, health-related retirement, and premature death in the Union, resulting in considerable social and economic costs. It is key to focus on prevention, combined with efforts to strengthen health systems in order to decrease the impact of non-communicable diseases on individuals and society and to reduce premature mortality towards reaching the Sustainable Development Goals by one third by 2030.

EU4Health will support disease prevention (including screening and early diagnosis for cancer) and health promotion programmes in Member States among others. EU4Health will contribute to the upscaling of the networking through the European Reference Networks, which are virtual networks and aim to facilitate discussion on complex, rare and non-communicable diseases, improving access to diagnosis and the provision of high-quality healthcare.

Will the programme contribute to the EU Beating Cancer Plan?

The pandemic has had a severe effect on cancer care, disrupting treatment, delaying diagnosis and vaccination, and affecting access to medicines. Even before the onset of COVID-19, cancer cases were estimated to increase by almost 25% by 2035, which will make it the leading cause of death in the EU. To reverse this worrying trend, the EU4Health Programme will also finance actions to fight cancer, which is one of the Commission’s main priorities. It will do so by providing funding to eligible legal entities established in Member States, such as health organisations and NGOs. Cancer will already be a strong priority in the first annual work programme for 2021, which will is expected to be adopted soon.

How will EU4Health address cross-border health threats?

The Commission is working to improve prevention, preparedness, surveillance and response to cross-border health threats. EU4Health can finance an EU reserve of medical, healthcare and support staff, and stockpiles of medical equipment.

Cross-border health threats require cross-border cooperation and the EU will play a larger role in supporting capacity and response. Beyond our own borders, the EU will support global cooperation on health challenges to improve health, reduce inequalities and increase protection against global health threats.

Will it also address shortages of medicines and personnel?

EU4Health can finance additional emergency reserves of medicines, medical devices and other health supplies to complement national reserves.

One way to make sure we have enough medical supplies is to use what we have more efficiently, in particular antimicrobials. Another way is to encourage European pharmaceutical production and innovation. EU4health will support the EU’s AMR Action Plan and the Pharmaceutical Strategy.

It will not be enough to have sufficient medicine and medical supplies. We also need a strong healthcare workforce, equipped with the necessary skills to face cross-border health threats. That is why EU4Health will also support healthcare workforce training in specific areas.

How will it improve health systems?

By making health systems more resilient, EU4Health will not only help prepare the EU to face future health crisis, but will also get Member States ready to face long-term challenges like an ageing population and health inequalities. Vulnerable groups need to have access to health services and healthcare, and inequalities between Member States and between regions in those Member States must be addressed.

When will the programme start?

Now adopted by the co-legislators, the EU4Health regulation will enter into force on the day of its publication in the Official Journal of the European Union and will apply retroactively from 1 January 2021. Next up is the preparation and adoption of the 2021 annual work programme, which is expected to prioritise crisis preparedness, disease prevention, health systems and digitalisation, as well as cancer as a transversal priority.

How much funding will be available under the EU4Health Programme and how will it be spent?

EU4Health will invest €5.1 billion over seven years to address health challenges. About €316 million are allocated to the first annual budget. Over its 7 year-lifetime, the programme will respect a number of provisions on total expenditure:

  • a minimum of 20% for health promotion and disease prevention;
  • a maximum of 12.5% for stockpiling crisis-relevant products at Union level;
  • a maximum of 12.5% for supporting global commitments and health initiatives;
  • a maximum of 8% for administrative expenses.

The programme should also contribute to mainstreaming climate action in the Union’s policies and the achievement of an overall expenditure target of at least 30% of the total amount of the Union budget and the EU Recovery Instrument on climate action.

How will EU4Health be implemented?

EU4Health will be implemented mainly by the Commission through direct management, including delegation to the executive agency. It will be implemented with eligible legal entities from Member States and third countries who will receive EU funding in the form of grants, prizes and procurement as well as indirect management by the relevant EU agencies such as European Medicines Agency or European Centre for Disease Control.

The new Health and Digital Executive Agency (HaDEA), that will be operational from 1 April, will be tasked with the roll-out and management of the annual work programmes.

The EU agencies – the European Centre for Disease Prevention and Control, and the European Medicines Agency – have a key role to play in Europe’s defence against serious cross-border health threats and pandemics, both on the prevention and on the crisis management front. The programme’s actions will enhance the work of these EU Agencies as well as of the European Food Safety Authority and the European Chemicals Agency.

To prepare the annual work programmes and monitor results, the EU4Health Regulation also sets up the consultative EU4Health Steering Group bringing together the European Commission and Member States. The Steering Group will be consulted on the annual priorities, contribute to ensure consistency and complementarity with Member States’ health policies, follow up the implementation of EU4Health and propose any necessary adjustments based on evaluations.

In addition, the Commission will consult with relevant stakeholders, including representatives of civil society and patient organisations, to seek their views on the needs to be addressed through the annual work programme, annual priorities and results.

The results of the stakeholder consultation and steering group discussions will be presented once a year to the European Parliament before the last Steering Group meeting.

Will the Commission continue to provide health funding through the European Social Fund + and other EU funds?

Whilst the EU4Health is the most ambitious health programme ever, important investments in health in the next long-term budget will also be made through other funding instruments working in synergy with EU4Health:

  • the European Social Fund Plus (ESF+) to support vulnerable groups in accessing healthcare;
  • the European Regional and Development Fund to improve regional health infrastructure;
  • Horizon Europe for health research and innovation;
  • rescEU to create emergency medical supplies;
  • the Digital Europe Programme for creating the digital infrastructure needed for digital health tools;
  • the Recovery and Resilience Facility for a stronger and more resilient EU from the current crisis.

Working across programmes and having shared objectives between policies will be key.

With the adoption of the EU4Health programme, the health strand of the proposal for the European Social Fund Plus (ESF+) is fully integrated into the EU4Health Programme.

How will the programme support research and innovation?

The EU4Health programme is an implementation tool for EU health policy and may support and encourage innovation regarding medicinal products and medical devices, and crisis-relevant products in the Union.

EU4Health will work closely with the European Commission’s main research programme, Horizon Europe, which includes a health cluster. Horizon Europe will finance research and innovation on topics such as life-long good health; environmental and social health determinants; non-communicable and rare diseases; infectious diseases; tools, technologies and digital solutions for health and care and healthcare systems. It will also include a Horizon Europe research & innovation mission on cancer, one of the Commission’s top priorities in health policy. The EU4Health Programme will help to ensure best use of research results and facilitate the uptake, scale-up and deployment of health innovation in healthcare systems and clinical practice.

Continue Reading

EU Politics

Coronavirus: A common path to Europe’s safe re-opening

Published

on

Ahead of the meeting of European leaders on 25 March, the Commission is calling on Member States to prepare for a coordinated approach to a gradual lifting of COVID-19 restrictions when the epidemiological situation will allow. In a Communication adopted today, it charts the way ahead for a balanced policy and common EU approach, pointing to what we need to do to advance the time when we can recover our European way of life, and do so in a safe and sustainable way with control over the virus.

While the epidemiological situation requires continued control until a sufficient vaccination coverage is achieved, the conditions must be created across the Single Market to allow for safe and sustained re-opening, so that citizens can enjoy their rights and economic and social activity can resume. This includes the deployment of a Digital Green Certificate covering vaccination, testing and recovery; the use of a common framework for response measures; guidance on additional testing strategies, such as wastewater monitoring to track variants; investment in diagnostics and treatments. The Communication also highlights actions to build global resilience through COVAX and an EU vaccine sharing mechanism.

Vice-President for Promoting our European Way of Life, Margaritis Schinas, said: “The common path forward requires a safe and sustainable approach for the benefit of all Europeans. In lifting restrictions, we must learn the lessons of 2020 and avoid damaging and costly cycles of opening and closing. Today’s Communication includes a balanced package of existing and new measures. We are looking forward to the endorsement of Member States at the upcoming European Council. Every day we get closer to achieving our vaccination goals and the recovery of our European way of life.”

Commissioner for Health and Food Safety, Stella Kyriakides, said: “Today we are proposing a common EU approach that will lead us on the way to our goal of re-opening the EU in a safe, sustainable and predictable way. The situation with the virus in Europe is still very challenging and confidence in decisions taken are crucial. It is only through a joint approach that we can return safely to full free movement in the EU, based on transparent measures and full mutual confidence.”

Key steps and tools set out by the Commission:

Digital Green Certificates

Today, the Commission has adopted a legislative proposal establishing a common framework for a Digital Green Certificate covering vaccination, testing and recovery. This is an EU level approach to issuing, verifying and accepting certificates to facilitate free movement within the EU, based on a strict respect for non-discrimination and of the fundamental rights of EU citizens.

A technical framework will be defined at EU level, to be put in place by mid-June, to ensure security, interoperability, as well as full compliance with personal data protection. It will also allow the possibility to extend to compatible certificates issued in third countries.

A European framework for COVID-19 response measures

The European Centre for Disease Prevention and Control is setting out a framework to help Member States take decisions on implementing restrictions. The approach will define tiers reflecting the epidemiological situation in each Member State. It will allow simulations to illustrate how much leeway each Member State has to reduce response measures without risking a reversal in the spread of the virus. An interactive digital tool developed by ECDC will be operational in April for use by Member States.

Guidance to support additional testing and tracing strategies

Self-tests for COVID-19 (both self-swabbing and self-testing kits) are now starting to enter the market. ECDC will publish today a technical guidance on COVID-19 self-tests, including details on their availability, their clinical performance compared to the “gold standard” RT-PCR tests, their implications for reporting and epidemiological surveillance, and the settings for their appropriate use.

The Commission is today adopting a Recommendation asking the Member States to put in place wastewater monitoring to track COVID-19 and its variants, share the data with competent health authorities for early detection of the presence of the virus, and identify clusters. It promotes the use of common methods for sampling, testing and data analysis, supported by a European exchange platform, and foresees respective financial support.

Data exchange between Member States’ contact tracing authorities can be particularly important when travellers are crossing borders in close proximity to each other, such as in airplanes or trains. Digital Passenger Locator Forms can be used by Member States to collect data from cross-border travellers entering their territory. In order for Member States to exchange relevant data through the exchange platform developed by the Commission and EASA, the Commission will publish draft measures establishing the necessary legal conditions for processing such personal data, to be adopted by the time of the summer travelling season.*

Investment in treatments

A common EU strategy on therapeutics is planned for mid-April to speed up research and manufacturing to ensure quick access to valuable treatments. More flexible regulatory measures for therapeutics, such as labelling facilitations, will be deployed to enable rapid supply at large scale during the pandemic.

Helping the tourism and culture sectors to prepare for safe re-opening

In the tourism and hospitality sector, the Commission has asked the Standardisation Organisation, CEN, to develop, in cooperation with industry and Member States, a voluntary sanitary seal to be used by establishments. This deliverable will be available by summer.

The Commission will promote EU cultural heritage sites and cultural routes, as well as cultural events and festivals, through an EU social media campaign on sustainable cultural tourism. New initiatives will be backed up when conditions allow through Erasmus+ and its DiscoverEU action to promote the discovery by young people of Europe’s cultural heritage by rail, during and beyond the European Year of Rail.

EU Vaccine Sharing Mechanism

A sustainable path out of the COVID-19 pandemic in the EU depends on progress at the global level. No country or region in the world will be safe from COVID-19 unless it is contained globally. The EU and its Member States are leading investment in the global COVAX Facility and are establishing a coordinated European approach to vaccine sharing by setting up an EU Vaccine Sharing Mechanism to help partner countries overcome the pandemic. The European approach to vaccine sharing will help neighbouring and partner countries overcome the pandemic and comes on top of the €2.2 billion EU investment from Team Europe (Commission, Member States and EIB) in COVAX.

Next Steps

The next months of the COVID-19 pandemic will require decisive action to ensure a sustainable and safe re-opening of our societies and economies. Coordinated action is needed at all levels to ensure that the next steps are as effective as possible in driving down the coronavirus, supporting citizens and businesses, and allowing our societies to return to a more normal situation. The EU set up a European bio-defence preparedness plan “HERA Incubator” against COVID-19 variants to bring together researchers, biotech companies, manufacturers, regulators and public authorities to monitor variants, exchange data and cooperate on adapting vaccines. Over the longer-term, the EU must also put in place a stronger framework for resilience and preparedness in the eventuality of future pandemics. This is already the objective of the proposals for a European Health Union.

The European Parliament and the Council should fast-track discussions, reach an agreement on the proposal for a Digital Green Certificate, and agree an approach to a safe opening based on a solid scientific framework. The European Commission will continue supporting the ramping up of vaccines production, and pursue technical solutions to increase interoperability of national systems to exchange data. Member States should accelerate vaccination programmes, ensure that temporary restrictions are proportionate and non-discriminatory, designate contact points to collaborate on wastewater surveillance and report on efforts made, and launch the technical implementation of the Digital Green Certificates in view of the fast-tracked adoption of the proposal.

In June 2021, upon request by the European Council, the European Commission will publish a paper on the lessons learnt from the pandemic and the way towards a more resilient future.

Continue Reading

Publications

Latest

Trending